Merck Kgaa Dm 5 (MKGAF) 101.4600 $MKGAF
Merck KGaA/Pfizer Avelumab in JAVELIN Ovarian 100 Study
Zacks Equity Research - Zacks Investment Research - Thu Jul 07, 3:54PM CDT
Merck (MKGAF) and Pfizer (PFE) initiated JAVELIN Ovarian 100 on avelumab, in combination with platinum-based chemotherapy, for the treatment of ovarian cancer.
GWPH: 94.83 (+1.36), UTHR: 111.16 (+1.58), PFE: 36.12 (+0.35)
Merck KGaA's Q1 Earnings Increase Y/Y, Offers 2016 View
Zacks Equity Research - Zacks Investment Research - Fri May 20, 9:33AM CDT
Merck KGaA (MKGAF) reported first-quarter 2016 earnings of $1.50 on sales of $4 billion.
BMRN: 91.49 (+3.33), PFE: 36.12 (+0.35), BMY: 75.28 (+1.20)
Merck KGaA (MKGAF) Q1 Earnings Increased Y/Y
Zacks Equity Research - Zacks Investment Research - Thu May 19, 2:24AM CDT
Merck KGaA (MKGAF) first-quarter 2016 earnings per American Depositary Receipt (ADR) came in at $1.5.
Merck KGaA (MKGAF) Q1 Earnings: What Awaits the Stock?
Zacks Equity Research - Zacks Investment Research - Mon May 16, 7:38AM CDT
Merck KGaA (MKGAF) is scheduled to report its first-quarter 2016 earnings results on May 19.
AXON: 13.07 (+0.16), BMRN: 91.49 (+3.33), PFE: 36.12 (+0.35)
Intrexon (XON) Q1 Loss Wider than Expected, Revenues Miss
Zacks Equity Research - Zacks Investment Research - Wed May 11, 9:30AM CDT
Intrexon Corporation (XON) reported a wider-than-expected first-quarter 2016 loss of 32 cents per share.
FCSC: 1.20 (+0.02), ANIP: 56.51 (-1.61), XON: 26.72 (+0.83)
Merck KGaA's Q4 Earnings Down Y/Y, Offers 2016 Outlook
Zacks Equity Research - Zacks Investment Research - Wed Mar 09, 8:20AM CST
Merck KGaA (MKGAF) reported fourth-quarter 2015 earnings of 32 cents, down 60.2% from the year over year.
GILD: 86.55 (+1.08), PFE: 36.12 (+0.35), HZNP: 18.71 (+0.52)
Merck KGaA (MKGAF) Q4 Earnings Decline Y/Y
Zacks Equity Research - Zacks Investment Research - Tue Mar 08, 3:02AM CST
Merck KGaA (MKGAF) fourth-quarter 2015 earnings per American Depositary Receipt (ADR) came in at 32 cents.
What Awaits Merck KGaA (MKGAF) this Earnings Season?
Zacks Equity Research - Zacks Investment Research - Mon Mar 07, 10:40AM CST
Merck KGaA (MKGAF) will be reporting its fourth-quarter 2015 earnings results on Mar 8.
BDSI: 2.58 (+0.07), BMRN: 91.49 (+3.33), PFE: 36.12 (+0.35)
Pfizer, Merck KGaA, Verastem Ovarian Cancer Study Tie-Up
Zacks Equity Research - Zacks Investment Research - Fri Mar 04, 3:00PM CST
Pfizer (PFE), Merck KGaA and Verastem tie up to evaluate avelumab in combination with VS-6063 for the treatment of ovarian cancer.
VSTM: 1.31 (+0.02), SNDX: 10.82 (+0.51), PFE: 36.12 (+0.35)
Pfizer & Merck KGaA Partner with Syndax for Ovarian Cancer
Zacks Equity Research - Zacks Investment Research - Tue Jan 05, 12:50PM CST
Pfizer (PFE) and Merck KGaA (MKGAF) teamed up with Syndax Pharmaceuticals to evaluate the avelumab/entinostat combination for ovarian cancer.
PFE: 36.12 (+0.35), HZNP: 18.71 (+0.52), ARNA: 1.70 (+0.06)
Pfizer/Merck KGaA Start Two Phase III Studies on Avelumab
Zacks Equity Research - Zacks Investment Research - Wed Dec 23, 3:30PM CST
Pfizer (PFE) and Merck KGaA announced the initiation of two phase III studies on avelumab for the treatment of ovarian cancer and urothelial cancer.
ACHN: 9.14 (+0.26), PFE: 36.12 (+0.35), ANIK: 53.30 (+0.94)
Pfizer/Merck KGaA Begin Two Phase III Studies on Avelumab
Zacks Equity Research - Zacks Investment Research - Thu Dec 10, 2:20PM CST
Pfizer (PFE) and Merck KGaA announced the initiation of two phase III studies on avelumab for the treatment of advanced or metastatic gastric/gastro-esophageal junction cancers.
ACHN: 9.14 (+0.26), PFE: 36.12 (+0.35), ANIK: 53.30 (+0.94)
Merck KGaA-Pfizer's Avelumab May Get Orphan Status in EU
Zacks Equity Research - Zacks Investment Research - Fri Nov 27, 1:40PM CST
Merck KGaA (MKGAF) and Pfizer (PFE) announced that the European Medicines Agency's (EMA) Committee for Orphan Medicinal Products (COMP) has issued a positive opinion for immunotherapy candidate, avelumab.
MRK: 59.35 (+0.57), PFE: 36.12 (+0.35), CORT: 6.01 (+0.14)
Pfizer's (PFE) Xalkori Positive in Another Phase III Study
Arpita Dutt - Zacks Investment Research - Thu Nov 19, 1:52PM CST
Pfizer's (PFE) Xalkori scored in another phase III study. The company also got breakthrough therapy status for avelumab.
AGN: 240.59 (+2.58), PFE: 36.12 (+0.35), LLY: 79.66 (+0.34)
Intrexon (XON) Reports Wider-than-Expected Loss in Q3
Zacks Equity Research - Zacks Investment Research - Tue Nov 10, 9:30AM CST
Intrexon Corporation (XON) reported third-quarter 2015 loss of 34 cents per share.
XON: 26.72 (+0.83), BXLT: 46.02 (-0.18), ANIK: 53.30 (+0.94)
Merck KGaA/Pfizer's Avelumab Gets Fast Track Status
Zacks Equity Research - Zacks Investment Research - Thu Oct 08, 1:50PM CDT
Merck KGaA (MKGAF) and Pfizer announced that avelumab received fast track status from the FDA for metastatic merkel cell carcinoma.
MRK: 59.35 (+0.57), PFE: 36.12 (+0.35), CORT: 6.01 (+0.14)
Merck KGaA's Pipeline on Track, Updates Key R&D Projects
Zacks Equity Research - Zacks Investment Research - Fri Oct 02, 3:40PM CDT
Merck KGaA (MKGAF) provided an update regarding the stages of development of its key immuno-oncology and oncology pipeline candidates.
ENDP: 17.42 (+0.14), PFE: 36.12 (+0.35), CORT: 6.01 (+0.14)
BioMarin (BMRN) to Acquire Rights to Phenylketonuria Drugs
Zacks Equity Research - Zacks Investment Research - Fri Oct 02, 3:10PM CDT
BioMarin (BMRN) announced that it has acquired all global rights to Kuvan and pegvaliase from Merck Serono, a division of Merck KGaA (MKGAF).
BMRN: 91.49 (+3.33), NVET: 4.95 (+0.15), REGN: 378.35 (+6.90)
Roche's Primary Progressive MS Drug Positive in Phase III
Zacks Equity Research - Zacks Investment Research - Mon Sep 28, 3:20PM CDT
Roche (RHHBY) announced encouraging results from the phase III ORATORIO study on ocrelizumab for primary progressive multiple sclerosis.
PFE: 36.12 (+0.35), LLY: 79.66 (+0.34), NVS: 82.13 (+0.33)
Merck KGaA/Pfizer Avelumab in JAVELIN Ovarian 100 Study
Zacks Equity Research - Zacks Investment Research - Thu Jul 07, 3:54PM CDT
Merck (MKGAF) and Pfizer (PFE) initiated JAVELIN Ovarian 100 on avelumab, in combination with platinum-based chemotherapy, for the treatment of ovarian cancer.
GWPH: 94.83 (+1.36), UTHR: 111.16 (+1.58), PFE: 36.12 (+0.35)
Merck KGaA's Q1 Earnings Increase Y/Y, Offers 2016 View
Zacks Equity Research - Zacks Investment Research - Fri May 20, 9:33AM CDT
Merck KGaA (MKGAF) reported first-quarter 2016 earnings of $1.50 on sales of $4 billion.
BMRN: 91.49 (+3.33), PFE: 36.12 (+0.35), BMY: 75.28 (+1.20)
Merck KGaA (MKGAF) Q1 Earnings Increased Y/Y
Zacks Equity Research - Zacks Investment Research - Thu May 19, 2:24AM CDT
Merck KGaA (MKGAF) first-quarter 2016 earnings per American Depositary Receipt (ADR) came in at $1.5.
Merck KGaA (MKGAF) Q1 Earnings: What Awaits the Stock?
Zacks Equity Research - Zacks Investment Research - Mon May 16, 7:38AM CDT
Merck KGaA (MKGAF) is scheduled to report its first-quarter 2016 earnings results on May 19.
AXON: 13.07 (+0.16), BMRN: 91.49 (+3.33), PFE: 36.12 (+0.35)
Intrexon (XON) Q1 Loss Wider than Expected, Revenues Miss
Zacks Equity Research - Zacks Investment Research - Wed May 11, 9:30AM CDT
Intrexon Corporation (XON) reported a wider-than-expected first-quarter 2016 loss of 32 cents per share.
FCSC: 1.20 (+0.02), ANIP: 56.51 (-1.61), XON: 26.72 (+0.83)
Merck KGaA's Q4 Earnings Down Y/Y, Offers 2016 Outlook
Zacks Equity Research - Zacks Investment Research - Wed Mar 09, 8:20AM CST
Merck KGaA (MKGAF) reported fourth-quarter 2015 earnings of 32 cents, down 60.2% from the year over year.
GILD: 86.55 (+1.08), PFE: 36.12 (+0.35), HZNP: 18.71 (+0.52)
Merck KGaA (MKGAF) Q4 Earnings Decline Y/Y
Zacks Equity Research - Zacks Investment Research - Tue Mar 08, 3:02AM CST
Merck KGaA (MKGAF) fourth-quarter 2015 earnings per American Depositary Receipt (ADR) came in at 32 cents.
What Awaits Merck KGaA (MKGAF) this Earnings Season?
Zacks Equity Research - Zacks Investment Research - Mon Mar 07, 10:40AM CST
Merck KGaA (MKGAF) will be reporting its fourth-quarter 2015 earnings results on Mar 8.
BDSI: 2.58 (+0.07), BMRN: 91.49 (+3.33), PFE: 36.12 (+0.35)
Pfizer, Merck KGaA, Verastem Ovarian Cancer Study Tie-Up
Zacks Equity Research - Zacks Investment Research - Fri Mar 04, 3:00PM CST
Pfizer (PFE), Merck KGaA and Verastem tie up to evaluate avelumab in combination with VS-6063 for the treatment of ovarian cancer.
VSTM: 1.31 (+0.02), SNDX: 10.82 (+0.51), PFE: 36.12 (+0.35)
Pfizer & Merck KGaA Partner with Syndax for Ovarian Cancer
Zacks Equity Research - Zacks Investment Research - Tue Jan 05, 12:50PM CST
Pfizer (PFE) and Merck KGaA (MKGAF) teamed up with Syndax Pharmaceuticals to evaluate the avelumab/entinostat combination for ovarian cancer.
PFE: 36.12 (+0.35), HZNP: 18.71 (+0.52), ARNA: 1.70 (+0.06)
Pfizer/Merck KGaA Start Two Phase III Studies on Avelumab
Zacks Equity Research - Zacks Investment Research - Wed Dec 23, 3:30PM CST
Pfizer (PFE) and Merck KGaA announced the initiation of two phase III studies on avelumab for the treatment of ovarian cancer and urothelial cancer.
ACHN: 9.14 (+0.26), PFE: 36.12 (+0.35), ANIK: 53.30 (+0.94)
Pfizer/Merck KGaA Begin Two Phase III Studies on Avelumab
Zacks Equity Research - Zacks Investment Research - Thu Dec 10, 2:20PM CST
Pfizer (PFE) and Merck KGaA announced the initiation of two phase III studies on avelumab for the treatment of advanced or metastatic gastric/gastro-esophageal junction cancers.
ACHN: 9.14 (+0.26), PFE: 36.12 (+0.35), ANIK: 53.30 (+0.94)
Merck KGaA-Pfizer's Avelumab May Get Orphan Status in EU
Zacks Equity Research - Zacks Investment Research - Fri Nov 27, 1:40PM CST
Merck KGaA (MKGAF) and Pfizer (PFE) announced that the European Medicines Agency's (EMA) Committee for Orphan Medicinal Products (COMP) has issued a positive opinion for immunotherapy candidate, avelumab.
MRK: 59.35 (+0.57), PFE: 36.12 (+0.35), CORT: 6.01 (+0.14)
Pfizer's (PFE) Xalkori Positive in Another Phase III Study
Arpita Dutt - Zacks Investment Research - Thu Nov 19, 1:52PM CST
Pfizer's (PFE) Xalkori scored in another phase III study. The company also got breakthrough therapy status for avelumab.
AGN: 240.59 (+2.58), PFE: 36.12 (+0.35), LLY: 79.66 (+0.34)
Intrexon (XON) Reports Wider-than-Expected Loss in Q3
Zacks Equity Research - Zacks Investment Research - Tue Nov 10, 9:30AM CST
Intrexon Corporation (XON) reported third-quarter 2015 loss of 34 cents per share.
XON: 26.72 (+0.83), BXLT: 46.02 (-0.18), ANIK: 53.30 (+0.94)
Merck KGaA/Pfizer's Avelumab Gets Fast Track Status
Zacks Equity Research - Zacks Investment Research - Thu Oct 08, 1:50PM CDT
Merck KGaA (MKGAF) and Pfizer announced that avelumab received fast track status from the FDA for metastatic merkel cell carcinoma.
MRK: 59.35 (+0.57), PFE: 36.12 (+0.35), CORT: 6.01 (+0.14)
Merck KGaA's Pipeline on Track, Updates Key R&D Projects
Zacks Equity Research - Zacks Investment Research - Fri Oct 02, 3:40PM CDT
Merck KGaA (MKGAF) provided an update regarding the stages of development of its key immuno-oncology and oncology pipeline candidates.
ENDP: 17.42 (+0.14), PFE: 36.12 (+0.35), CORT: 6.01 (+0.14)
BioMarin (BMRN) to Acquire Rights to Phenylketonuria Drugs
Zacks Equity Research - Zacks Investment Research - Fri Oct 02, 3:10PM CDT
BioMarin (BMRN) announced that it has acquired all global rights to Kuvan and pegvaliase from Merck Serono, a division of Merck KGaA (MKGAF).
BMRN: 91.49 (+3.33), NVET: 4.95 (+0.15), REGN: 378.35 (+6.90)
Roche's Primary Progressive MS Drug Positive in Phase III
Zacks Equity Research - Zacks Investment Research - Mon Sep 28, 3:20PM CDT
Roche (RHHBY) announced encouraging results from the phase III ORATORIO study on ocrelizumab for primary progressive multiple sclerosis.
PFE: 36.12 (+0.35), LLY: 79.66 (+0.34), NVS: 82.13 (+0.33)
